8-K: Danaher to Acquire Masimo for $9.9 Billion

Danaher Corporation announced a definitive agreement to acquire Masimo Corporation for $180 per share in cash, totaling approximately $9.9 billion.

Summary

• Danaher Corporation has entered into an Agreement and Plan of Merger to acquire all outstanding shares of Masimo Corporation's common stock.
• The acquisition price is $180.00 per share in cash, without interest.
• The total enterprise value of the transaction is approximately $9.9 billion, including assumed indebtedness and net of acquired cash.
• This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2027 estimated EBITDA including the full benefit of expected annual synergies.
• Masimo will operate as a standalone company within Danaher's Diagnostics segment, alongside Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics.
• The transaction is expected to close in the second half of 2026, subject to customary conditions including regulatory clearances and Masimo shareholder approval.
• Danaher plans to fund the acquisition using cash on hand and proceeds from debt financing.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive strategic move, given the strong strategic fit, expected EPS accretion, and significant synergy potential. The acquisition of a market leader in a growing segment enhances Danaher's long-term growth profile.

Positives

• Masimo is expected to be accretive to Danaher's adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year post-acquisition.
• Expected accretion increases to approximately $0.70 in the fifth full year following completion of the acquisition.
• Masimo is projected to deliver high-single digit core revenue growth over the long-term, accelerating Danaher's Diagnostics segment core revenue growth profile.
• Danaher anticipates realizing more than $125 million of annual cost synergies and over $50 million of annual revenue synergies by the fifth full year.
• Masimo's advanced sensor technology and AI-enabled monitoring capabilities will strengthen Danaher's diagnostics portfolio.
• The acquisition is seen as an exceptional strategic fit, enhancing Danaher's position in pulse oximetry and patient monitoring solutions.

Risks

• Uncertainties regarding the timing of the transaction.
• Risk that the transaction may not be completed on anticipated terms, in a timely manner, or at all.
• Failure to satisfy any conditions to consummation, including required approval by Masimo's stockholders.
• Possibility of competing offers or acquisition proposals for Masimo.
• Failure to receive required regulatory approvals from governmental entities, or conditions/limitations placed on such approvals.
• Occurrence of any event that could lead to termination of the merger agreement, potentially requiring Masimo to pay a termination fee.
• Potential adverse effects on Masimo's or Danaher's ability to retain and hire key personnel, maintain customer/supplier relationships, or impact operating results due to the announcement/pendency of the transaction.
• Risks related to diverting management's attention from ongoing business operations.
• Risk of stockholder litigation in connection with the transaction, potentially resulting in significant costs.
• Certain restrictions during the pendency of the transaction that may impact Masimo's or Danaher's ability to pursue business opportunities.
• Risk that announcements relating to the transaction could adversely affect the market price of Masimo's or Danaher's common stock, especially if the transaction is not consummated.
• Risks that the benefits of the transaction are not realized when and as expected.
• Impact of legislative, regulatory, and economic developments.

Future Outlook

Danaher expects the acquisition of Masimo to be accretive to adjusted diluted net earnings per common share, with Masimo contributing high-single digit core revenue growth over the long-term, thereby accelerating Danaher's Diagnostics segment growth profile. Significant annual cost and revenue synergies are anticipated by the fifth full year post-acquisition.

Management Comments

• Rainer M. Blair, President and CEO of Danaher, stated: 'We are excited to welcome the Masimo team to Danaher. We've followed this innovative company for many years and see it as an exceptional strategic fit for Danaher. Masimo is a leader in pulse oximetry and other patient monitoring solutions, which combined with its trusted brand and differentiated technology, will greatly strengthen our diagnostics franchise. With the Danaher Business System and our global scale, we see opportunities to expand Masimo's reach and continue improving outcomes for patients, particularly those in acute care settings.'
• Julie Sawyer Montgomery, Executive Vice President for Diagnostics at Danaher, commented: 'Masimo's advanced sensor technology and AI-enabled monitoring bring powerful new capabilities to our diagnostics portfolio. Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and improve decision making in critical settings.'

Industry Context

StockSavvy.ai notes that this acquisition significantly strengthens Danaher's position in the high-growth patient monitoring and specialty diagnostics market. By integrating Masimo's leading pulse oximetry and AI-enabled monitoring solutions, Danaher is enhancing its diagnostics segment, aligning with broader industry trends towards advanced, integrated healthcare technologies and data-driven clinical decision-making. This move positions Danaher to capitalize on the increasing demand for sophisticated patient monitoring in acute care settings.

Legal Proceedings

• Risk of stockholder litigation in connection with the transactions contemplated by the merger agreement, which may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Masimo stockholders will receive a cash premium for their shares, providing immediate liquidity and a return on investment.
• Danaher shareholders are expected to benefit from EPS accretion, accelerated revenue growth in the Diagnostics segment, and significant synergies.
• Employees of both companies may experience changes related to integration, with a stated risk regarding retention of key personnel.
• Customers of Masimo may benefit from expanded reach and continued innovation under Danaher's ownership and the Danaher Business System.
• Suppliers and business partners may be impacted by changes in operational structure and procurement processes post-acquisition.

Next Steps

• Masimo and Danaher intend to file relevant materials with the SEC, including Masimo's proxy statement.
• Masimo will mail the definitive proxy statement and a proxy card to its stockholders.
• The consummation of the merger is subject to customary conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
• Receipt of certain non-U.S. antitrust and foreign direct investment approvals is required.
• Masimo shareholder approval is required.
• The transaction is anticipated to close in the second half of 2026.

Key Dates

Recommendation

The acquisition of Masimo represents a strong strategic move for Danaher, enhancing its high-growth Diagnostics segment with a leading player in patient monitoring. The expected EPS accretion, high-single digit core revenue growth for Masimo, and substantial cost and revenue synergies indicate a financially beneficial transaction. While integration risks and regulatory approvals exist, the long-term strategic fit and projected financial uplift make Danaher an attractive 'buy' for investors seeking exposure to a strengthened healthcare technology portfolio.

Keywords

Danaher, Masimo, Acquisition, Merger, Diagnostics, Patient Monitoring, Pulse Oximetry, Healthcare Technology, Life Sciences, M&A